Disease/Infection News

RSS

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice – still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

8 Jul 2010

Researchers use nanotechnology to develop advanced wound dressing to detect, treat infection

Researchers are using nanotechnology to develop a medical dressing which will detect and treat infection in wounds. Scientists at the University of Bath and the burns team at the Southwest UK Paediatric Burns Centre at Frenchay Hospital in Bristol are working together with teams across Europe and Australia to create an advanced wound dressing.

8 Jul 2010

AHF denounces Obama administration plan to address AIDS drug crisis with $25M

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, will host a press teleconference tomorrow, Thursday, July 8th at 10:00 AM Pacific/1:00 PM Eastern, to denounce an Obama administration plan to address AIDS drug crisis with an insufficient $25 million as "too little, too late."

8 Jul 2010

Increasing HAART treatment for HIV/AIDS patients will provide significant cost savings: Study

Increasing highly active antiretroviral therapy treatment for people with HIV/AIDS will provide significant cost savings over a relatively short period of time, according to a formal economic analysis led by researchers at the BC Centre for Excellence in HIV/AIDS (BC-CfE) at Providence Health Care and the University of British Columbia.

8 Jul 2010

Medizone seeks international patent protection for Asepticsure technology

Medizone International, Inc. has filed an international patent application under the auspices of the Patent Co-operation Treaty (PCT) to secure international patent protection for its Asepticsure™ technology. The international patent application consolidates the two previously filed patent applications titled "Healthcare Facility Disinfecting System" and "Disinfecting Process and Apparatus."

8 Jul 2010

TB Alliance, DNDi announce inter-PDP agreement to develop potential anti-TB compounds

The Global Alliance for TB Drug Development and Drugs for Neglected Diseases initiative announced today a unique first-ever royalty-free license agreement between two not-for-profit drug developers that speeds progress toward markedly improved therapy of multiple neglected diseases. The TB Alliance has granted rights to DNDi to develop a class of potential anti-TB compounds that also show significant promise for treating other neglected diseases that largely affect the world's poor.

8 Jul 2010

LSUHSC awarded $4M grant to study cannabinoid treatment for HIV infection

Patricia Molina, MD, PhD, Professor and Head of Physiology at LSU Health Sciences Center New Orleans, has been awarded a $4 million grant over five years by the National Institute on Drug Abuse of the National Institutes of Health to study how cannabinoids, the principal psychoactive component of marijuana, produce subtle changes in gene activity that affect how a person responds to HIV infection.

8 Jul 2010

Drug initiative granted rights to develop TB compounds for potential treatment of NTDs

The Drugs for Neglected Diseases Initiative now has the rights to "develop a class of potential anti-[tuberculosis] compounds" for the treatment of Chagas disease, African sleeping sickness and leishmaniasis, Reuters reports (Nebehay, 7/7).

8 Jul 2010

FDA approves Beech Tree Labs' IND for Phase 1/2a clinical evaluation of BTL-TML-HSV

Beech Tree Labs, Inc., announced today that the FDA has approved its IND for a Phase 1/2a clinical evaluation of BTL-TML-HSV, a novel therapeutic agent for treating recurrent oral herpes infections. The study will be a 210 patient, multi-site, placebo-controlled trial and is anticipated to begin later this summer.

8 Jul 2010

NIH awards $2.8M grant for development of diagnostic multiplex testing platform with BMB technology

Applied BioCode, Inc. and Maxwell Sensors Inc. announced today that they have received a $2.8M three-year grant from the Recovery Act Limited Competition: National Institutes of Health (NIH), for the development of a high throughput diagnostic multiplex testing platform using their Barcoded Magnetic Beads (BMB) technology for various high value immunodiagnostics and molecular diagnostic tests.

7 Jul 2010

PolyMedix receives NIH grant to develop defensin-mimetic antimicrobial compounds for malaria

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a grant from the National Institute of Health (NIH) to support the development of defensin-mimetic antimicrobial compounds for the treatment of malaria.

7 Jul 2010

Codex Alimentarius Commission provides new guidance to help improve food safety

The maximum amount of melamine allowed in powdered infant formula is 1 mg/kg and the amount of the chemical allowed in other foods and animal feed is 2.5 mg/kg, according to new rulings from the United Nations' food standards body, Codex Alimentarius Commission.

7 Jul 2010

TWINCORE researchers develop new model approaches for HCV research

The hepatitis C virus is highly specialised. We humans are its natural hosts. The only other living organisms that could be infected with the hepatitis C virus in the lab are chimpanzees. Nevertheless it is - from the viewpoint of the virus - highly successful: around 170 million people are chronically infected with the virus. And with the chronic infection the risk of developing liver cancer also increases.

7 Jul 2010

Communication between bacterial species promotes resistance to antibiotics: Study

Ear infections caused by more than one species of bacteria could be more persistent and antibiotic-resistant because one pathogen may be communicating with the other, encouraging it to bolster its defenses. Interrupting or removing that communication could be key to curing these infections. Researchers from Wake Forest University Baptist Medical Center publish their findings today in mBio-, the online open-access journal of the American Society for Microbiology.

7 Jul 2010

QIAGEN receives CE conformity marking for careHPV Test

QIAGEN has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries, the company announced today at the International Papillomavirus Conference in Montreal, Canada. The CE conformity marking ("Conformite Europeenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark.

From QIAGEN Manchester Limited 7 Jul 2010

WHO H1N1 response probe's second meeting highlights divergent views

The independent team of health experts responsible for reviewing the WHO's response to H1N1 (swine flu) wrapped up a second round of public hearings on Friday, "during which members heard testimony from widely divergent groups, from health officials to some of its most public critics," CIDRAP News reports.

7 Jul 2010

AIDS Healthcare Foundation presses Obama Administration on PEPFAR funding

The AIDS Healthcare Foundation (AHF), "[t]he largest global AIDS organization[,] accused the Obama administration and Congress on Friday of falling short on promised funding and oversight in the worldwide fight against the epidemic," The Hill's "Healthwatch" blog reports.

7 Jul 2010

Bacteria that will kill Dengue bearing mosquitoes on the way

Dengue is a deadly viral fever spread by mosquito bites that kills thousands around the world each year. Now researchers from James Cook University and University of Queensland are working on a bacterium called Wolbachia that can stop the spread of this virus.

6 Jul 2010

Three Rivers Pharmaceuticals receives FDA expanded labeling for INFERGEN

Three Rivers Pharmaceuticals, LLC, today received expanded labeling from the U.S. Food and Drug Administration (FDA) to include daily use of INFERGEN (Consensus Interferon) in combination with ribavirin (RBV) for retreatment of chronic hepatitis C patients. The expanded labeling targets hepatitis C patients who need retreatment.

6 Jul 2010

Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published

Sangamo BioSciences, Inc. announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.

6 Jul 2010

Disease/Infection News

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Researchers use nanotechnology to develop advanced wound dressing to detect, treat infection

AHF denounces Obama administration plan to address AIDS drug crisis with $25M

Increasing HAART treatment for HIV/AIDS patients will provide significant cost savings: Study

Medizone seeks international patent protection for Asepticsure technology

TB Alliance, DNDi announce inter-PDP agreement to develop potential anti-TB compounds

LSUHSC awarded $4M grant to study cannabinoid treatment for HIV infection

Drug initiative granted rights to develop TB compounds for potential treatment of NTDs

FDA approves Beech Tree Labs' IND for Phase 1/2a clinical evaluation of BTL-TML-HSV

NIH awards $2.8M grant for development of diagnostic multiplex testing platform with BMB technology

PolyMedix receives NIH grant to develop defensin-mimetic antimicrobial compounds for malaria

Codex Alimentarius Commission provides new guidance to help improve food safety

TWINCORE researchers develop new model approaches for HCV research

Communication between bacterial species promotes resistance to antibiotics: Study

QIAGEN receives CE conformity marking for careHPV Test

WHO H1N1 response probe's second meeting highlights divergent views

AIDS Healthcare Foundation presses Obama Administration on PEPFAR funding

Bacteria that will kill Dengue bearing mosquitoes on the way

Three Rivers Pharmaceuticals receives FDA expanded labeling for INFERGEN

Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News